September 28, 2026 · Journal of hepatology · DOI: 10.1016/j.jhep.2026.08.028

EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy.

Listen to this summary

This joint EASL-EASD-EASO guidance addresses how to use resmetirom (80/100 mg orally) and semaglutide (2.4 mg weekly subcutaneously) as MASH-targeted therapies in adults with metabolic dysfunction-associated steatohepatitis, covering candidate selection, initiation, monitoring, and discontinuation. The authors recommend pharmacotherapy for non-cirrhotic MASH with fibrosis stages 2-3, with the choice individualized by cardiometabolic profile: semaglutide is preferred for patients with obesity, type 2 diabetes, or established cardiovascular disease, while resmetirom may be prioritized for those without obesity or already on or intolerant to GLP-1 receptor agonists. In MASH cirrhosis, the drugs appear safe but are not recommended as MASH-targeted treatment until liver-related benefits are demonstrated.

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play